Cargando…

The European challenges of funding orphan medicinal products

BACKGROUND: Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU). OBJECTIVES: To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as well as to compare the public expenditures on OMPs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szegedi, Márta, Zelei, Tamás, Arickx, Francis, Bucsics, Anna, Cohn-Zanchetta, Emanuelle, Fürst, Jurij, Kamusheva, Maria, Kawalec, Pawel, Petrova, Guenka, Slaby, Juraj, Stawowczyk, Ewa, Vocelka, Milan, Zechmeister-Koss, Ingrid, Kaló, Zoltán, Molnár, Mária Judit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219168/ https://www.ncbi.nlm.nih.gov/pubmed/30396361 http://dx.doi.org/10.1186/s13023-018-0927-y

Ejemplares similares

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
por: Zelei, Tamás, et al.
Publicado: (2016)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
por: Petrova, Guenka, et al.
Publicado: (2017)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Mechanism of coordinated access to orphan drugs
por: DeRidder, R, et al.
Publicado: (2012)

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
por: Dimitrova, Maria, et al.
Publicado: (2014)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2018)

Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Possible long COVID healthcare pathways: a scoping review
por: Wolf, Sarah, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland
por: Stawowczyk, Ewa, et al.
Publicado: (2016)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Disease activity, quality of life, and indirect costs of ulcerative colitis in Poland
por: Kawalec, Paweł, et al.
Publicado: (2017)

Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2023)

The Fund for Widows and Orphans of Medical Officers
Publicado: (1873)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
por: Morel, Thomas, et al.
Publicado: (2013)

Regulation and financing of prenatal screening and diagnostic tests for fetal anomalies in Europe
por: Reinsperger, I, et al.
Publicado: (2022)

Medical Subordinate Officers' Widows' and Orphans' Fund
Publicado: (1868)

Warrant Medical Officers' Widows' and Orphans' Fund
Publicado: (1868)

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
por: Kolasa, Katarzyna, et al.
Publicado: (2018)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
por: Morrell, Liz, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nefo3qr00sht5aldhvefd1qeis